Can Optum Offset UnitedHealth's Health Benefits Growth Woes?

UnitedHealth Group is increasingly relying on its Optum business to offset challenges in its UnitedHealthcare health benefits segment, as Optum's revenue growth has consistently outpaced UnitedHealthcare's from 2022-2024; in 2024, Optum accounted for over half of UnitedHealth's total operating income. Despite a Change Healthcare cyberattack creating setbacks, analysts expect Optum to remain UNH's key profit driver, while UNH's shares have underperformed the industry year-to-date, and 2025 earnings are projected to decline 19.5%.

Analysis

UnitedHealth Group (UNH) is increasingly dependent on its Optum division to counterbalance significant headwinds in its UnitedHealthcare benefits segment, which faces pressure from rising medical costs, especially within Medicare Advantage. Optum has become UNH's primary growth driver, evidenced by its revenue growth consistently outperforming UnitedHealthcare from 2022 to 2024 (e.g., Optum's 24% growth versus UnitedHealthcare's 12.7% in 2023) and contributing over half of UNH's total operating income in 2024. While strategic investments in Optum Health's integrated care model are underway, the early 2024 Change Healthcare cyberattack exposed operational vulnerabilities and resulted in financial setbacks. UNH's historical five-year profit growth of 13% outpaces Humana's approximate 1% decline and is slightly ahead of Elevance Health's 11.3%, with UNH reporting a Q1 2025 adjusted net margin of 6%. However, UNH shares have significantly underperformed the industry year-to-date, falling 38.1% compared to the industry's 27.6% decline. The stock's valuation appears elevated, with a forward price-to-earnings ratio of 13.18 against an industry average of 11.95. This valuation is particularly concerning as consensus estimates project a substantial 19.5% drop in 2025 earnings per share to $22.28, leading to a Zacks Rank #5 (Strong Sell) and reflecting a strongly negative sentiment for the stock.

Key Decisions for Investors

• Investors should exercise significant caution regarding UnitedHealth Group, given the projected 19.5% decline in 2025 earnings, its current Zacks Rank #5 (Strong Sell), and strongly negative sentiment, despite Optum's robust underlying growth.
• Closely monitor Optum's ability to continue offsetting the margin compression within the core UnitedHealthcare business, particularly in the challenged Medicare Advantage segment, and assess any lingering financial or operational repercussions from the Change Healthcare cyberattack.
• Re-evaluate investment theses considering UNH's notable year-to-date share price underperformance and its premium forward P/E ratio relative to the industry, especially in the context of the adverse earnings outlook and prevailing bearish signals.